Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment

OBJECTIVES: To report the impact of continued burosumab treatment on clinical laboratory tests of efficacy, patient-reported outcomes (PROs) and ambulatory function in adults with X-linked hypophosphataemia who continued from a 96-week phase 3 study into a 48-week open-label extension. METHODS: Elig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamenicky, Peter, Briot, Karine, Brandi, Maria Luisa, Cohen-Solal, Martine, Crowley, Rachel K, Keen, Richard, Kolta, Sami, Lachmann, Robin H, Lecoq, Anne-Lise, Ralston, Stuart H, Walsh, Jennifer S, Rylands, Angela J, Williams, Angela, Sun, Wei, Nixon, Annabel, Nixon, Mark, Javaid, Muhammad K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980374/
https://www.ncbi.nlm.nih.gov/pubmed/36854566
http://dx.doi.org/10.1136/rmdopen-2022-002676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980374/
https://www.ncbi.nlm.nih.gov/pubmed/36854566
http://dx.doi.org/10.1136/rmdopen-2022-002676

Ejemplares similares